It was always riskier than AVXL. Showing actual results that can highlight the lack of a dose response curve is brave, but probably also foolhardy. In an arena with a 99.6% failure rate.... best to drag ones feet and never release details about dose response like AVXL. Too bad for severe Alzheimer's suffers. The compassionate use success highlights the power of the placebo effect, even in the most severe cases imho.